Table 3.
Pharmacokinetic measures of sumatriptan.
| Placebo and sumatriptana (reference) n = 34 | Erenumab and sumatriptan (test) n = 20 | |
|---|---|---|
| Cmax (ng/ml) | ||
| LS meanb | 83.50 | 79.00 |
| Ratioc,d, (90% CI) | 0.95 (0.82, 1.09) | |
| AUC6hr (hr*ng/ml) | ||
| LS meanb | 133.33 | 130.59 |
| Ratioc,d, (90% CI) | 0.98 (0.93, 1.03) | |
| AUC∞ (hr*ng/ml) | ||
| LS meanb | 144.32 | 144.81 |
| Ratioc,d, (90% CI) | 1.00 (0.96, 1.05) | |
AUC: area under the plasma concentration–time curve; AUC6hr: AUC from time 0 to 6 hours; AUC∞: AUC from time 0 to infinity; Cmax: maximum observed plasma concentration; CI: confidence interval; LS: least squares.
Table is based on the safety analysis set.
a
Subjects receiving sumatriptan are from group A and group B; subjects in group B received erenumab on day 5 in part 2.
b
LS geometric mean using the SAS PROC MIXED procedure, version 9.3 (SAS Institute Inc., Cary, NC, USA). cRatios are test/reference.
d
The ratio and CI are based on natural log scale data converted back to the original scale.